WO2020227713A1 - Compositions and methods for the treatment of leukodystrophy and whole animal and cellular models for the identifying efficacious agents for treatment of the same - Google Patents

Compositions and methods for the treatment of leukodystrophy and whole animal and cellular models for the identifying efficacious agents for treatment of the same Download PDF

Info

Publication number
WO2020227713A1
WO2020227713A1 PCT/US2020/032364 US2020032364W WO2020227713A1 WO 2020227713 A1 WO2020227713 A1 WO 2020227713A1 US 2020032364 W US2020032364 W US 2020032364W WO 2020227713 A1 WO2020227713 A1 WO 2020227713A1
Authority
WO
WIPO (PCT)
Prior art keywords
tubb4a
mice
nucleic acid
cells
leukodystrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/032364
Other languages
English (en)
French (fr)
Inventor
Akshata ALMAD
Adeline L. VANDERVER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Children's Hospital of Philadelphia
Original Assignee
Children's Hospital of Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP20801706.1A priority Critical patent/EP3966336A4/en
Priority to AU2020268878A priority patent/AU2020268878A1/en
Priority to US17/610,050 priority patent/US20220265862A1/en
Priority to CN202080049838.3A priority patent/CN114127300A/zh
Priority to KR1020217039551A priority patent/KR20220007092A/ko
Priority to CA3139521A priority patent/CA3139521A1/en
Application filed by Children's Hospital of Philadelphia filed Critical Children's Hospital of Philadelphia
Priority to JP2021566128A priority patent/JP2022532874A/ja
Publication of WO2020227713A1 publication Critical patent/WO2020227713A1/en
Anticipated expiration legal-status Critical
Priority to JP2025065950A priority patent/JP2025118647A/ja
Priority to US19/391,899 priority patent/US20260151513A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
    • A01K2217/056—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to mutation of coding region of the transgene (dominant negative)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Definitions

  • This invention relates to the fields of leukodystrophy and improved therapeutics for ameliorating symptoms of this disorder.
  • the invention also provides a whole animal model for identifying agents useful for the treatment or prevention of leukodystrophy, particularly H-ABC.
  • H-ABC affected individuals are within this spectrum, presenting in the toddler years, typically with dystonia (Hersheson et al, 2013), progressive gait impairment, speech and cognitive deficits. They are further delineated from other individuals with mutations in TUBB4A by characteristic neuroimaging features: hypomyelination and atrophy of the caudate and putamen along with cerebellar atrophy (van der Knaap et al., 2007).
  • H-ABC Asp249Asn (24.1% of overall mutations in a cohort of 166 individuals, referred to hereafter as TUBB4A D249N ).
  • H-ABC is currently considered an intermediary phenotype, between severely affected early infantile variants and juvenile-adult mild variants (Nahhas N, 2016).
  • FIG.3U-3V Representative western blot images (Fig.3U) and quantification (Fig.3V) of normalized MBP protein levels at P21 and ES of WT, Tubb4a D249N and Tubb4a D249N/D249N mice in forebrain.
  • FIG.3W-3X Representative ES images (Fig.3W) and quantification (Fig.3X) of MBP (red) at P14, P21 and ES of WT, Tubb4a D249N and
  • Figures 7A- 7J Tubb4a D249N/D249N mice display reduced number of oligodendrocytes (OL)
  • FIG.7A Schematic diagram displaying the time course of immunohistochemical assays.
  • FIG. 7B Schematic diagram showing area of corpus callosum used to perform counts.
  • FIG.7C Representative images of ASPA positive OL in WT, Tubb4a D249N and Tubb4a D249N/D249N mice at the end-stage (ES).
  • Scale bar 50 ⁇ m and 25 ⁇ m (Fig.7F) Quantification of double positive NG2+ Olig2+ counts/mm 2 at P14, P21 and ES in WT, Tubb4a D249N and
  • RNA interference RNA interference
  • dsRNA double stranded RNA
  • hypomyelinating atrophy of basal ganglia and cerebellum is a rare leukodystrophy which our group has identified to be caused by sporadic de novo heterozygous mutations in the TUBB4A gene (Simons et al.2013).
  • Monoallelic mutations in TUBB4A may result in a spectrum of neurologic disorders ranging from an early onset encephalopathy to an adult-onset Dystonia type 4 (whispering dysphonia).
  • H-ABC affected individuals are within this spectrum, presenting in the toddler years, typically with dystonia (Hersheson et al.2013), progressive gait impairment, speech and cognitive deficits.
  • WT tubulin overexpression can rescue mutant tubulin models.
  • altering the stoichiometry of tubulins, by increasing WT versus mutated TUBB4A in affected cells, would arrest the neurodegeneration in H-ABC.
  • proprietary capsids will effectively target our cells of interest, in primate models.
  • novel viral vectors will target SN, CGC and/or OL to overexpress WT TUBB4A and rescue the phenotype in vitro. Targeting these vectors would improve therapeutic approaches targeted to involved cell types (OL, striatal neurons and cerebellar granule neurons).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Environmental Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
PCT/US2020/032364 2019-05-09 2020-05-11 Compositions and methods for the treatment of leukodystrophy and whole animal and cellular models for the identifying efficacious agents for treatment of the same Ceased WO2020227713A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2020268878A AU2020268878A1 (en) 2019-05-09 2020-05-11 Compositions and methods for the treatment of leukodystrophy and whole animal and cellular models for identifying efficacious agents for treatment of the same
US17/610,050 US20220265862A1 (en) 2019-05-09 2020-05-11 Compositions and methods for the treatment of leukodystrophy and whole animal and cellular models for identifying efficacious agents for treatment of the same
CN202080049838.3A CN114127300A (zh) 2019-05-09 2020-05-11 用于治疗脑白质营养不良的组合物和方法以及用于鉴定治疗脑白质营养不良的有效药物的完整动物和细胞模型
KR1020217039551A KR20220007092A (ko) 2019-05-09 2020-05-11 대뇌백질이영양증의 치료용 조성물 및 방법과 그것의 치료에 효과적인 작용제를 확인하기 위한 전체 동물 및 세포 모델
CA3139521A CA3139521A1 (en) 2019-05-09 2020-05-11 Compositions and methods for the treatment of leukodystrophy and whole animal and cellular models for identifying efficacious agents for treatment of the same
EP20801706.1A EP3966336A4 (en) 2019-05-09 2020-05-11 COMPOSITIONS AND METHODS FOR THE TREATMENT OF LEUKODYSTROPHY AND WHOLE ANIMAL AND CELLULAR MODELS FOR THE IDENTIFICATION OF EFFECTIVE AGENTS FOR TREATING THE SAME
JP2021566128A JP2022532874A (ja) 2019-05-09 2020-05-11 白質ジストロフィーの治療のための組成物および方法、ならびに白質ジストロフィーの治療のための有効な薬剤を同定するための動物全体および細胞モデル
JP2025065950A JP2025118647A (ja) 2019-05-09 2025-04-12 白質ジストロフィーの治療のための組成物および方法、ならびに白質ジストロフィーの治療のための有効な薬剤を同定するための動物全体および細胞モデル
US19/391,899 US20260151513A1 (en) 2019-05-09 2025-11-17 Compositions and methods for the treatment of leukodystrophy and whole animal and cellular models for identifying efficacious agents for treatment of the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962845637P 2019-05-09 2019-05-09
US62/845,637 2019-05-09
US201962924910P 2019-10-23 2019-10-23
US62/924,910 2019-10-23

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US17/610,050 A-371-Of-International US20220265862A1 (en) 2019-05-09 2020-05-11 Compositions and methods for the treatment of leukodystrophy and whole animal and cellular models for identifying efficacious agents for treatment of the same
US19/391,899 Division US20260151513A1 (en) 2019-05-09 2025-11-17 Compositions and methods for the treatment of leukodystrophy and whole animal and cellular models for identifying efficacious agents for treatment of the same

Publications (1)

Publication Number Publication Date
WO2020227713A1 true WO2020227713A1 (en) 2020-11-12

Family

ID=73051654

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/032364 Ceased WO2020227713A1 (en) 2019-05-09 2020-05-11 Compositions and methods for the treatment of leukodystrophy and whole animal and cellular models for the identifying efficacious agents for treatment of the same

Country Status (8)

Country Link
US (2) US20220265862A1 (cg-RX-API-DMAC7.html)
EP (1) EP3966336A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022532874A (cg-RX-API-DMAC7.html)
KR (1) KR20220007092A (cg-RX-API-DMAC7.html)
CN (1) CN114127300A (cg-RX-API-DMAC7.html)
AU (1) AU2020268878A1 (cg-RX-API-DMAC7.html)
CA (1) CA3139521A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020227713A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022221777A1 (en) * 2021-04-16 2022-10-20 The Children's Hospital Of Philadelphia Compositions and methods useful for the treatment of h-abc leukodystrophy
JP2024505350A (ja) * 2020-12-29 2024-02-06 ザ ジャクソン ラボラトリー 歩行および姿勢の分析

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115992208B (zh) * 2022-08-03 2026-06-26 三峡大学 一种GLD模型Twitcher小鼠基因型的鉴定引物和鉴定方法
US20250092365A1 (en) * 2023-09-14 2025-03-20 ReGen Theranostics, Inc. Method of manufacturing autologous cardiac lineage cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180110806A1 (en) * 1999-08-05 2018-04-26 Regents Of The University Of Minnesota Multipotent Adult Stem Cells and Methods for Isolation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101914547A (zh) * 2010-07-28 2010-12-15 北京华阜康生物科技股份有限公司 转人app双突变基因老年痴呆症小鼠模型的建立和应用
EP3249403A4 (en) * 2015-01-21 2019-01-16 Konica Minolta, Inc. PHOSPHORAGGREGATNANOPARTICLES FOR FLUORESCENT OBSERVATION
EP3286318A2 (en) * 2015-04-22 2018-02-28 Mina Therapeutics Limited Sarna compositions and methods of use
DK3302522T3 (da) * 2015-06-02 2022-09-26 Academisch Ziekenhuis Leiden Midler og fremgangsmåde til behandling af facioscapulohumeral muskeldystrofi (fshd)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180110806A1 (en) * 1999-08-05 2018-04-26 Regents Of The University Of Minnesota Multipotent Adult Stem Cells and Methods for Isolation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JULIAN CURIEL, GUILLERMO RODRÍGUEZ BEY, ASAKO TAKANOHASHI, MARIANNA BUGIANI, XIAOQIN FU, NICOLE I WOLF, BRUCE NMEZI, RAPHAEL SCHIF: "TUBB4A mutations result in specific neuronal and oligodendrocytic defects that closely match clinically distinct phenotypes", HUMAN MOLECULAR GENETICS, vol. 26, no. 22, 29 August 2017 (2017-08-29) - 15 November 2017 (2017-11-15), pages 4506 - 4518, XP055759988 *
See also references of EP3966336A4 *
YUKI MIYAMOTO, TORII TOMOHIRO, KAWAHARA KAZUKO, HASEGAWA NANAMI, TANOUE AKITO, SEKI YOICHI, MORIMOTO TAKAKO, FUNAKOSHI-TAGO MEGUMI: "Data on the effect of hypomyelinating leukodystrophy 6 (HLD6)-associated mutations on the TUBB4A properties", DATA IN BRIEF, vol. 11, no. 2017, 16 February 2017 (2017-02-16) - April 2017 (2017-04-01), pages 284 - 289, XP055759980 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024505350A (ja) * 2020-12-29 2024-02-06 ザ ジャクソン ラボラトリー 歩行および姿勢の分析
JP7851936B2 (ja) 2020-12-29 2026-04-27 ザ ジャクソン ラボラトリー 歩行および姿勢の分析
WO2022221777A1 (en) * 2021-04-16 2022-10-20 The Children's Hospital Of Philadelphia Compositions and methods useful for the treatment of h-abc leukodystrophy
JP2024515289A (ja) * 2021-04-16 2024-04-08 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア H-abc白質ジストロフィーの治療に有用な組成物および方法

Also Published As

Publication number Publication date
US20220265862A1 (en) 2022-08-25
CA3139521A1 (en) 2020-11-12
AU2020268878A1 (en) 2021-12-02
JP2022532874A (ja) 2022-07-20
JP2025118647A (ja) 2025-08-13
CN114127300A (zh) 2022-03-01
EP3966336A1 (en) 2022-03-16
EP3966336A4 (en) 2023-11-01
KR20220007092A (ko) 2022-01-18
US20260151513A1 (en) 2026-06-04

Similar Documents

Publication Publication Date Title
Philips et al. MCT1 deletion in oligodendrocyte lineage cells causes late-onset hypomyelination and axonal degeneration
Bennett et al. Senataxin mutations elicit motor neuron degeneration phenotypes and yield TDP-43 mislocalization in ALS4 mice and human patients
Klim et al. Connecting TDP-43 pathology with neuropathy
Sanuki et al. miR-124a is required for hippocampal axogenesis and retinal cone survival through Lhx2 suppression
Emery et al. Myelin gene regulatory factor is a critical transcriptional regulator required for CNS myelination
Peier et al. (Over) correction of FMR1 deficiency with YAC transgenics: behavioral and physical features
Morandell et al. Cul3 regulates cytoskeleton protein homeostasis and cell migration during a critical window of brain development
Oliveras-Salva et al. Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice
JP2025118647A (ja) 白質ジストロフィーの治療のための組成物および方法、ならびに白質ジストロフィーの治療のための有効な薬剤を同定するための動物全体および細胞モデル
Wang et al. Cytoplasmic mislocalization of RNA splicing factors and aberrant neuronal gene splicing in TDP-43 transgenic pig brain
Tran et al. Notch signaling plays a dual role in regulating the neuron-to-oligodendrocyte switch in the developing dorsal forebrain
JP6309450B2 (ja) セロトニン関連の医学的状態、アドレナリン関連の医学的状態、ノルアドレナリン関連の医学的状態、グルタミン酸関連の医学的状態および副腎皮質刺激ホルモン放出ホルモン関連の医学的状態の処置および診断のためのミクロrnaおよび該ミクロrnaを含む組成物
US8609617B2 (en) KLF family members regulate intrinsic axon regeneration ability
Mende et al. Deficiency of the splicing factor Sfrs10 results in early embryonic lethality in mice and has no impact on full-length SMN/Smn splicing
Thompson et al. HD and SCA1: Tales from two 30-year journeys since gene discovery
Wang et al. AAV2-mediated gene therapy for Bietti crystalline dystrophy provides functional CYP4V2 in multiple relevant cell models
Li et al. LONRF2 is a protein quality control ubiquitin ligase whose deficiency causes late-onset neurological deficits
Jeong et al. Micro-scale control of oligodendrocyte morphology and myelination by the intellectual disability-linked protein acyltransferase ZDHHC9
Ren et al. DiGeorge syndrome critical region gene 2 (DGCR2), a schizophrenia risk gene, regulates dendritic spine development through cell adhesion
US20240200065A1 (en) Compositions and methods useful for the treatment of h-abc leukodystrophy
Collins et al. FBXW7 regulates MYRF levels to control myelin capacity and homeostasis in the adult CNS
Baughn Therapeutic Restoration of Stathmin-2 RNA Processing in TDP-43 Proteinopathies
Obeid et al. Neuron-specific WWOX gene therapy produces dose-dependent, durable rescue in a model of WWOX-related epileptic encephalopathy
Andersen The novel long noncoding RNA Pnky regulates neurogenesis and neural stem cell maintenance in vivo
Yang et al. HnRNP G Reduces Neuron Death in Amyotrophic Lateral Sclerosis by Preventing Abnormal TDP-43 Accumulation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20801706

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3139521

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021566128

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20217039551

Country of ref document: KR

Kind code of ref document: A

Ref document number: 2020268878

Country of ref document: AU

Date of ref document: 20200511

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020801706

Country of ref document: EP

Effective date: 20211209